Table 5 Discontinuation rates for the olanzapine long-acting injection and olanzapine oral studies
OLZ LAI (N = 404) | Oral Study 1 (N = 335) | Oral Study 2 (N = 431) | Oral Study 3 (N = 152) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
PLC (n = 98) | OLZ LAI (n = 306)a | PLC (n = 68) | HAL (n = 68) | OLZ (n = 198)a | 1 mg (n = 88) | HAL (n = 81) | OLZ (n = 262)a | PLC (n = 50) | 1 mg (n = 52) | OLZ (n = 50) | |
Discontinued (%) | |||||||||||
All Causeb | 42.9 | 31.0 | 67.6 | 56.5 | 56.1 | 44.3 | 46.9 | 37.8 | 80.0 | 76.9 | 62.0 |
Lack of Efficacy | 24.5 | 11.4 | 47.1 | 27.5 | 32.3 | 18.2 | 19.8 | 14.1 | 74.0 | 61.5 | 56.0 |
Patient Decision | 9.2 | 11.8 | 2.9 | 10.1 | 10.6 | 9.1 | 7.4 | 7.3 | 5.8 | 2.0 | 2.0 |
Adverse Event | 5.1 | 4.2 | 10.3 | 8.7 | 5.1 | 11.4 | 14.8 | 10.7 | 0.0 | 9.6 | 4.0 |
Lost at Follow- up | 1.0 | 0.7 | 1.5 | 7.2 | 3.0 | 1.1 | 2.5 | 1.5 | 4.0 | 0.0 | 0.0 |